Model‐Based Drug Development in Oncology: What's Next?

Publisher： John Wiley & Sons Inc

E-ISSN： 1532-6535|93|4|303-305

ISSN： 0009-9236

Source： CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol.93, Iss.4, 2013-04, pp. : 303-305

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Model‐Based Drug Development: A Rational Approach to Efficiently Accelerate Drug Development

By  

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 93, Iss. 6, 2013-06 ,pp. : 502-514

John Wiley & Sons Inc

Access to resources Recommend Favorite

Evaluation of drug–drug interactions for oncology therapies: in vitro–in vivo extrapolation model‐based risk assessment

By  

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 79, Iss. 6, 2015-06 ,pp. : 946-958

John Wiley & Sons Inc

Access to resources Recommend Favorite

Geriatric Oncology: How Far Have We Gone and What Are the Next Steps?

By  

Oncology, Vol. 77, Iss. 3-4, 2009-07 ,pp. : 147-156

Karger

Access to resources Recommend Favorite

What is a new drug worth? An innovative model for performance‐based pricing

By  

EUROPEAN JOURNAL OF CANCER CARE (ELECTRONIC), Vol. 24, Iss. 3, 2015-05 ,pp. : 313-320

John Wiley & Sons Inc

Access to resources Recommend Favorite

A matrix approach to guide IHC‐based tissue biomarker development in oncology drug discovery

By  

THE JOURNAL OF PATHOLOGY, Vol. 232, Iss. 2, 2014-01 ,pp. : 190-198

John Wiley & Sons Inc

Access to resources Recommend Favorite